CTOs on the Move

Talecris Plasma

www.talecrisplasma.com

 
Talecris Plasma is a Corpus Christi, TX-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
  • Number of Employees: 250-1000
  • Annual Revenue: $10-50 Million

Executives

Name Title Contact Details

Similar Companies

AeroCare Holdings

AeroCare Holdings is a Orlando, FL-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Blue Cross Blue Shield of Michigan

Blue Cross Blue Shield of Michigan is one of the leading providers in Healthcare, Pharmaceuticals, and Biotech. It is based in Detroit, MI. To find more information about Blue Cross Blue Shield of Michigan, please visit www.bcbsm.com

Davis Memorial Hospital

At Davis Health System, our goal is excellence—and we have the support of nearly 1,000 healthcare professionals in reaching that goal. We are committed to providing patient-friendly, quality healthcare to our communities in five regional counties. We do it by offering technology that`s equal to that of larger hospitals, expertise that is backed by continuing education and services that focus on the specific healthcare needs of our friends and neighbors. As impressive as our facilities, equipment and credentials are, it`s the caring nature of our professionals that defines us.

Sunquest Information Systems

Sunquest Information Systems, Inc. provides healthcare information systems to large and mid-sized hospitals, clinics and other facilities, including integrated delivery networks comprised of multi-entity, multi-site healthcare organizations.

SetPoint Medical

SetPoint Medical is developing novel neuromodulation therapies to treat those who suffer from inflammatory diseases such as Crohn`s Disease and rheumatoid arthritis. The company is developing a proprietary and innovative neuromodulation therapy delivery platform consisting of a micro-regulator programmed via a unique prescription pad based interface. This novel therapy will provide patients and healthcare providers with a safe and efficacious alternative to drugs, while costing payors less than 50% of what today`s leading biologic therapies cost.